The Mount Sinai Health System is an integrated health care system providing exceptional medical care to our local and global communities.
Encompassing the Icahn School of Medicine and eight hospital campuses in the New York metropolitan area, as well as a large, regional ambulatory footprint, Mount Sinai is internationally acclaimed for its excellence in research, patient care, and education across a range of specialties.
The Mount Sinai Health System was created from the combination of the Mount Sinai Medical Center and Continuum Health Partners, which both agreed unanimously to combine the two entities in July 2013.
The Health System is designed to increase efficiencies and economies of scale; improve quality and outcomes; and expand access to advanced primary, specialty, and ambulatory care services throughout a wide clinical network.
The Health System includes more than 7,000 primary and specialty care physicians and 12 minority-owned free-standing ambulatory surgery centers.
Mount Sinai also features a robust and continually expanding network of multispecialty services, including more than 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island.
It has more than 40 clinical and academic relationships with other local health care organizations. Mount Sinai physicians can be found in more than 300 community locations throughout the New York metropolitan area.
As a university, Karolinska Institutet is Sweden’s single largest centre of medical academic research and offers the country’s widest range of medical courses and programmes.
Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine.
Karolinska Institutet was founded by King Karl XIII in 1810 as an "academy for the training of skilled army surgeons". Today, Karolinska Institutet is a modern medical university and one of the foremost in the world.
With our close relationship to the clinical milieu, a well-established infrastructure and a stable financial situation, Karolinska Institutet has excellent prerequisites for sustaining high quality research and education.
Established in June 2013, the Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre (KI-AZ ICMC) represents a unique and exciting opportunity for academic scientists to collaborate and work side-by-side with scientists from the pharmaceutical industry to discover and develop the next generation of medicines to treat cardiovascular and metabolic diseases.
Under the leadership of Professor Christer Betsholtz, twelve open, integrated and collaborative research groups are focusing on preclinical and clinical studies. The aim of the centre is to advance the understanding of cardiovascular and metabolic disease within three main strategic areas; Cardiac Regeneration, Islet Health (Diabetes) and Diabetic Nephropathy.